<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>254792</rcn>
  <id>101112687</id>
  <acronym>NanoLymphoma</acronym>
  <teaser>Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line treatment in patients with B-cell lymphoma. However, diffuse large B-cell lymphoma (DLBCL), the most...</teaser>
  <objective><![CDATA[Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line treatment in patients with B-cell lymphoma. However, diffuse large B-cell lymphoma (DLBCL), the most common and aggressive form of B-cell lymphoma worldwide, is still incurable in 40% of patients. These patients have poor prognosis due to treatment failure or relapse upon therapy with CD20-antibodies (260,000 mortalities worldwide in 2020). 
Thus, there is urgent need for novel therapies to overcome resistance and enhance anti-tumor activities in patients with aggressive B-cell lymphoma. 

We developed nanofilaments that can efficiently cluster multiple lymphoma membrane targets (CD20, and new targets: CD22, CD37) to induce potent tumor cytotoxicity. This new therapeutic platform (''NanoLymphoma'') represents a powerful strategy since this approach is independent from genetic cancer subtypes and is broadly applicable in molecular heterogeneous B-cell lymphoma subtypes. NanoLymphoma will evaluate and validate the technical and commercial feasibility of its new therapeutic platform to target human lymphoma cells and prepare for clinical translation to patients with DLBCL. NanoLymphoma will: 1) Show that clustering of therapeutic targets on the surface tumor cells potently induces tumor cell death, and 2) Perform market and business case analyses to ensure commercial feasibility and entry to market through Simmunext Biotherapeutics. NanoLymphoma is expected to outperform conventional anti-CD20 antibody treatment in patients with aggressive lymphoma.]]></objective>
  <title>Novel therapeutic platform for aggressive lymphoma: NanoLymphoma</title>
  <totalCost>0</totalCost>
  <ecMaxContribution>150000</ecMaxContribution>
  <startDate>2023-09-01</startDate>
  <endDate>2025-02-28</endDate>
  <ecSignatureDate>2023-06-08</ecSignatureDate>
  <duration>18</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101112687</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate readOnly="true">2023-07-24 18:08:54</contentCreationDate>
  <contentUpdateDate>2023-07-24 18:07:05</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-09-19 14:48:35</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <rcn>456154</rcn>
        <id>456154-nanofilament-therapy-for-aggressive-lymphoma</id>
        <title>Nanofilament therapy for aggressive lymphoma</title>
        <contentUpdateDate>2025-05-08 14:56:49</contentUpdateDate>
        <relations>
          <categories>
            <category classification="applicationDomain" type="isApplicableIn">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/health</code>
              <title>Health</title>
              <displayCode readOnly="true">/Health</displayCode>
            </category>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode readOnly="true">/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode readOnly="true">/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55606</rcn>
        <title>ERC-2022-POC2</title>
        <identifier>ERC-2022-POC2</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="150000" terminated="false" sme="false" netEcContribution="150000" totalCost="0" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1969372</rcn>
        <id>892057785</id>
        <vatNumber>NL861608884B01</vatNumber>
        <legalName>STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM</legalName>
        <shortName>RADBOUDUMC</shortName>
        <address>
          <street>GEERT GROOTEPLEIN 10 ZUID</street>
          <city>NIJMEGEN</city>
          <postalCode>6525 GA</postalCode>
          <country>NL</country>
          <geolocation>51.8236065,5.8598165</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/HES</code>
              <title>Higher or Secondary Education Establishments</title>
              <displayCode readOnly="true">/Higher or Secondary Education Establishments</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Arnhem/Nijmegen</name>
              <rcn>391389318</rcn>
              <nutsCode>NL226</nutsCode>
              <parents>
                <region>
                  <name>Gelderland</name>
                  <rcn>391389352</rcn>
                  <nutsCode>NL22</nutsCode>
                  <parents>
                    <region>
                      <name>Oost-Nederland</name>
                      <rcn>391391784</rcn>
                      <nutsCode>NL2</nutsCode>
                      <parents>
                        <region>
                          <name>Netherlands</name>
                          <rcn>391547432</rcn>
                          <nutsCode>NL</nutsCode>
                          <euCode>NL</euCode>
                          <isoCode>NL</isoCode>
                        </region>
                      </parents>
                    </region>
                  </parents>
                </region>
              </parents>
            </region>
            <region type="relatedRegion">
              <name>Netherlands</name>
              <rcn>391547432</rcn>
              <nutsCode>NL</nutsCode>
              <euCode>NL</euCode>
              <isoCode>NL</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705727</rcn>
        <id>HORIZON.1.1</id>
        <code>HORIZON.1.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.1.1</pga>
        <title>European Research Council (ERC)</title>
        <parent>
          <programme>
            <rcn>705726</rcn>
            <code>HORIZON.1</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>706736</rcn>
        <id>HORIZON_ERC-2022-POC2</id>
        <code>ERC-2022-POC2</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>ERC PROOF OF CONCEPT GRANTS2</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1281732</rcn>
        <id>101112687_PSHORIZON</id>
        <title>Periodic Reporting for period 1 - NanoLymphoma (Novel therapeutic platform for aggressive lymphoma: NanoLymphoma)</title>
        <teaser>The problem: Poor clinical outcome of patients with aggressive B-cell lymphoma after immunotherapy. Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-04-15 01:27:45</sourceUpdateDate>
        <contentUpdateDate>2025-04-15 01:27:45</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1281516</rcn>
        <id>101112687_138699_PUBLIHORIZON</id>
        <title>Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia Associated With Diffuse Large B-cell Lymphoma</title>
        <details>
          <authors>Madeleine R. Berendsen; Diede A.G. van Bladel; Eva Hesius; Cristina Berganza Irusquieta; Jos Rijntjes; Annemiek B. van Spriel; Ellen van der Spek; Johannes F.M. Pruijt; Leonie I. Kroeze; Konnie M. Hebeda; Sandra Croockewit; Wendy B.C. Stevens; J Han J.M. van Krieken; Patricia J.T.A. Groenen; Michiel van den Brand; Blanca Scheijen</authors>
          <journalNumber/>
          <journalTitle>HemaSphere</journalTitle>
          <publishedPages/>
          <publishedYear>2023</publishedYear>
          <publisher>Wiley</publisher>
        </details>
        <identifiers>
          <doi>10.1097/HS9.0000000000000976</doi>
          <issn>2572-9241</issn>
        </identifiers>
        <sourceUpdateDate>2025-04-15 01:27:45</sourceUpdateDate>
        <contentUpdateDate>2025-08-05 12:54:53</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode readOnly="true">/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode readOnly="true">/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1278536</rcn>
        <id>101112687_138698_PUBLIHORIZON</id>
        <title>Mutational profile dynamics in follicular lymphoma and large cell transformation</title>
        <details>
          <authors>Eva A M Hesius; Wendy B C Stevens; James P Stewart; Leonie I Kroeze; Ellen van der Spek; Djamila Issa; Peet Nooijen; Jeroen Luijks; David Gonzalez; Patricia J T A Groenen; Nicole M A Blijlevens; Annemiek B van Spriel; Michiel van den Brand</authors>
          <journalNumber/>
          <journalTitle>Journal of Clinical Pathology</journalTitle>
          <publishedPages/>
          <publishedYear>2025</publishedYear>
          <publisher>BMJ Group</publisher>
        </details>
        <identifiers>
          <doi>10.1136/jcp-2024-209880</doi>
          <issn>1472-4146</issn>
        </identifiers>
        <sourceUpdateDate>2025-03-31 14:59:57</sourceUpdateDate>
        <contentUpdateDate>2025-04-08 08:16:25</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode readOnly="true">/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode readOnly="true">/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1278547</rcn>
        <id>101112687_138700_PUBLIHORIZON</id>
        <title>Membrane organization by tetraspanins and galectins shapes lymphocyte function</title>
        <details>
          <authors>Laia Querol Cano; Vera-Marie E. Dunlock; Fabian Schwerdtfeger; Annemiek B. van Spriel</authors>
          <journalNumber/>
          <journalTitle>Nature Reviews Immunology</journalTitle>
          <publishedPages/>
          <publishedYear>2023</publishedYear>
          <publisher>Springer</publisher>
        </details>
        <identifiers>
          <doi>10.1038/s41577-023-00935-0</doi>
          <issn>1474-1741</issn>
        </identifiers>
        <sourceUpdateDate>2025-03-31 14:59:57</sourceUpdateDate>
        <contentUpdateDate>2025-04-08 08:16:25</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/publication</code>
              <title>Project publication</title>
              <description>Result: Project publications</description>
              <displayCode readOnly="true">/Project publication</displayCode>
            </category>
            <category classification="projectPublication" type="isPublishedAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PEER_REVIEWED_ARTICLE</code>
              <title>Peer reviewed articles</title>
              <displayCode readOnly="true">/Peer reviewed articles</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/29/101/553/1353</code>
        <title>mortality</title>
        <displayCode readOnly="true">/social sciences/sociology/demography/mortality</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/35/155/643</code>
        <title>immunotherapy</title>
        <displayCode readOnly="true">/medical and health sciences/basic medicine/immunology/immunotherapy</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-ERC-POC</code>
        <title>HORIZON ERC Proof of Concept Grants</title>
        <description>HORIZON ERC Proof of Concept Grants</description>
        <displayCode readOnly="true">/HORIZON ERC Proof of Concept Grants</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
